Canyon Pharmaceuticals: Study Finds Desirudin Superior to Enoxaparin in Patients with Poor Kidney Function Undergoing Orthopedic Surgery  
5/2/2011 8:44:34 AM

PARSIPPANY, N.J.--(BUSINESS WIRE)--Desirudin reduced major venous thromboembolism (VTE) and post-operative bleeding compared with the standard of care, enoxaparin, in patients with poor kidney function undergoing orthopedic surgery, according to a poster presented at the Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) meeting.